EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis

Remo Panaccione iD, Silvio Danese iD, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D R Higgins, Edward V Loftus iD, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard und 6 weitere

Alimentary Pharmacology & Therapeutics · 2024-02 · 59 (3) · 393-408

DOI: 10.1111/apt.17816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 27.11.2023. Verfasst von Remo Panaccione und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Janus Kinase Inhibitors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Upadacitinib is an oral, selective Janus kinase inhibitor.

Aim

To assess the efficacy and safety of upadacitinib in patients with moderate‐to‐severe ulcerative colitis following 16‐week extended induction therapy, and 52‐week maintenance therapy in patients achieving clinical response after 16‐week extended induction therapy Methods Patients without clinical response to 8 weeks' upadacitinib 45 mg once daily induction therapy in two induction trials were eligible for an additional 8 weeks of therapy. Patients achieving clinical response at Week 16 were subsequently re‐randomised (1:1) to upadacitinib 15 or 30 mg once daily for 52‐week maintenance therapy. Efficacy was assessed at induction Week 16 (integrated) and maintenance Week 52; safety was assessed throughout.

Results

Overall, 127/663 (19.2%) patients did not achieve clinical response to upadacitinib 45 mg at Week 8 and received an additional 8 weeks of therapy; 75/127 (59.1%) subsequently achieved clinical response at Week 16 and entered the maintenance trial. At Week 52, 26.5% of patients receiving upadacitinib 15 mg, and 43.6% receiving 30 mg, achieved clinical remission; efficacy was observed across all other endpoints with both doses. Herpes zoster rates increased with longer duration (16 weeks) of exposure to upadacitinib 45 mg during induction compared with the same population during the first 8 weeks. No other new safety signals were observed, and results are otherwise consistent with the known safety profile of upadacitinib.

Conclusions

Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy, may benefit from an additional 8 weeks of therapy. Clinical trial registration: NCT02819635; NCT03653026

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeJanus Kinase InhibitorsHumansHeterocyclic Compounds, 3-RingInduction ChemotherapyDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

clinical pharmacologyimmunosuppressioninflammatory bowel diseaseoutcomes researchulcerative colitis

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.
  • Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy.
  • AbbVie Inc, North Chicago, Illinois, USA.
  • Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
  • Department of Gastroenterology and Clinical Nutrition, CHU de Nice, Université Côte d'Azur, Nice, France.

ORCID-Profile: Remo Panaccione, Silvio Danese, Edward V Loftus, Jean-Frédéric Colombel

Förderung

  • AbbVie

Zitieren

APA

Panaccione, R., Danese, S., Zhou, W., Klaff, J., Ilo, D., Yao, X., Levy, G., Higgins, P. D. R., Loftus, E. V., Chen, S., Gonzalez, Y. S., Leonard, C., Hébuterne, X., Lindsay, J. O., Cao, Q., Nakase, H., Colombel, J. F., & Vermeire, S. (2024). Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis. Alimentary Pharmacology & Therapeutics, 59(3), 393-408. https://doi.org/10.1111/apt.17816

Vancouver

Panaccione R, Danese S, Zhou W, Klaff J, Ilo D, Yao X, et al. Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis. Alimentary Pharmacology & Therapeutics. 2024;59(3):393-408. doi:10.1111/apt.17816

BibTeX
@article{Panaccione2024,
  author = {Panaccione, Remo and Danese, Silvio and Zhou, Wen and Klaff, Justin and Ilo, Dapo and Yao, Xuan and Levy, Gweneth and Higgins, Peter D R and Loftus, Edward V and Chen, Su and Gonzalez, Yuri Sanchez and Leonard, Carolyn and Hébuterne, Xavier and Lindsay, James O and Cao, Qian and Nakase, Hiroshi and Colombel, Jean-Frédéric and Vermeire, Séverine},
  title = {Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {3},
  pages = {393--408},
  doi = {10.1111/apt.17816}
}
Kostenlos starten →